Literature DB >> 33457002

High expression of the TEFM gene predicts poor prognosis in hepatocellular carcinoma.

Zai-Yi Fei1,2, Wei-Si Wang3,4, Su-Fen Li3,4, Jia-Ji Zi3, Li Yang1,2, Ting Liu1,2, Song Ao1,2, Qian-Qian Liu1,2, Qing-Hua Cui1,2, Min Yu1,2, Wei Xiong3,4.   

Abstract

BACKGROUND: Mitochondrial transcription elongation factor (TEFM) is an essential molecule that regulates the replication-transcription switch of mitochondrial DNA. TEFM modulates both transcription elongation and RNA processing in mitochondria. The purpose of the present study was to determine the association of TEFM with tumor progression and prognosis in hepatocellular carcinoma (HCC) patients.
METHODS: The different protein expression level of TEFM among HCC cell lines was detected by Western blotting. The gene expression profiling interactive analysis (GEPIA) was used to dynamically analyze the mRNA expression of TEFM gene in different stages of HCC. The protein and mRNA expression levels of TEFM were detected by immunohistochemistry, Western blotting and qRT-PCR. The mRNA-SeqV2 expression of TEFM and clinical information of HCC patients were downloaded from the TCGA database by using R3.6.3 software. Next, the relationships between the expression level of TEFM and clinicopathological characteristics and the prognostic value of TEFM were analyzed. A Cox regression model was used for multivariate analysis of the factors that affected the prognosis of HCC. Finally, the association between the expression levels of TEFM and other mitochondrial regulatory genes and HCC biomarker genes was analyzed by GEPIA.
RESULTS: TEFM is upregulated in HCC cell lines compared to noncancerous liver cell line. TEFM protein and mRNA expression levels in HCC tissues were significantly upregulated compared with those in noncancerous liver tissues. In addition, the mRNA expression level of TEFM was significantly correlated with sex, serum AFP level, and vascular invasion (P<0.05). Further analysis showed that high expression level of TEFM was unfavorable in terms of the prognosis of patients with HCC. Cox multivariate regression analysis showed that patient age, vascular invasion, and TEFM expression were independent factors affecting the prognosis of HCC patients (P<0.05). The expression level of the TEFM gene was significantly positively correlated with the expression of multiple mitochondrial regulatory genes and biomarker genes of HCC (P<0.01, R>0).
CONCLUSIONS: Our findings reveal that TEFM may play an important role in the progression of HCC. More importantly, the elevated expression of TEFM may potentially predict poor overall survival (OS) and disease-free survival (DFS) in patients with HCC. 2020 Journal of Gastrointestinal Oncology. All rights reserved.

Entities:  

Keywords:  Mitochondrial transcription elongation factor (TEFM); TCGA dataset; hepatocellular carcinoma (HCC); immunohistochemistry; prognosis

Year:  2020        PMID: 33457002      PMCID: PMC7807266          DOI: 10.21037/jgo-20-120

Source DB:  PubMed          Journal:  J Gastrointest Oncol        ISSN: 2078-6891


  34 in total

1.  Meeting report: mitochondrial DNA and cancer epidemiology.

Authors:  Mukesh Verma; Robert K Naviaux; Masashi Tanaka; Deepak Kumar; Claudio Franceschi; Keshav K Singh
Journal:  Cancer Res       Date:  2007-01-09       Impact factor: 12.701

2.  Mitochondria and metabolic homeostasis.

Authors:  Zhiyong Cheng; Michael Ristow
Journal:  Antioxid Redox Signal       Date:  2013-03-28       Impact factor: 8.401

Review 3.  Structural basis of mitochondrial transcription.

Authors:  Hauke S Hillen; Dmitry Temiakov; Patrick Cramer
Journal:  Nat Struct Mol Biol       Date:  2018-09-06       Impact factor: 15.369

4.  A high expression of MTERF3 correlates with tumor progression and predicts poor outcomes in patients with brain glioma.

Authors:  Jiaji Zi; Weisi Wang; Meitao Sun; Wen Mei; Sufen Li; Bin Li; Yang Xiao; Zaiyi Fei; Ruopeng Zhang; Min Yu; Wei Xiong
Journal:  Int J Clin Exp Pathol       Date:  2019-05-01

Review 5.  Epigenetic biomarkers in liver cancer.

Authors:  Krishna K Banaudha; Mukesh Verma
Journal:  Methods Mol Biol       Date:  2015

6.  Mitochondrial copy number and risk of breast cancer: a pilot study.

Authors:  Jie Shen; Mary Platek; Amjad Mahasneh; Christine B Ambrosone; Hua Zhao
Journal:  Mitochondrion       Date:  2009-09-27       Impact factor: 4.160

Review 7.  Transarterial Therapies for Hepatocellular Carcinoma.

Authors:  Ezio Lanza; Matteo Donadon; Dario Poretti; Vittorio Pedicini; Marco Tramarin; Massimo Roncalli; Hyungjin Rhee; Young Nyun Park; Guido Torzilli
Journal:  Liver Cancer       Date:  2016-11-29       Impact factor: 11.740

8.  Origins and functional consequences of somatic mitochondrial DNA mutations in human cancer.

Authors:  Young Seok Ju; Ludmil B Alexandrov; Moritz Gerstung; Inigo Martincorena; Serena Nik-Zainal; Manasa Ramakrishna; Helen R Davies; Elli Papaemmanuil; Gunes Gundem; Adam Shlien; Niccolo Bolli; Sam Behjati; Patrick S Tarpey; Jyoti Nangalia; Charles E Massie; Adam P Butler; Jon W Teague; George S Vassiliou; Anthony R Green; Ming-Qing Du; Ashwin Unnikrishnan; John E Pimanda; Bin Tean Teh; Nikhil Munshi; Mel Greaves; Paresh Vyas; Adel K El-Naggar; Tom Santarius; V Peter Collins; Richard Grundy; Jack A Taylor; D Neil Hayes; David Malkin; Christopher S Foster; Anne Y Warren; Hayley C Whitaker; Daniel Brewer; Rosalind Eeles; Colin Cooper; David Neal; Tapio Visakorpi; William B Isaacs; G Steven Bova; Adrienne M Flanagan; P Andrew Futreal; Andy G Lynch; Patrick F Chinnery; Ultan McDermott; Michael R Stratton; Peter J Campbell
Journal:  Elife       Date:  2014-10-01       Impact factor: 8.140

9.  Primary clear cell renal carcinoma cells display minimal mitochondrial respiratory capacity resulting in pronounced sensitivity to glycolytic inhibition by 3-Bromopyruvate.

Authors:  H Nilsson; D Lindgren; A Mandahl Forsberg; H Mulder; H Axelson; M E Johansson
Journal:  Cell Death Dis       Date:  2015-01-08       Impact factor: 8.469

10.  Immunohistochemical angiogenic biomarkers in hepatocellular carcinoma and cirrhosis: correlation with pathological features.

Authors:  Osmar Damasceno Ribeiro; Nathalie Henriques Silva Canedo; Vera Lucia Pannain
Journal:  Clinics (Sao Paulo)       Date:  2016-11-01       Impact factor: 2.365

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.